Cancer Genomics.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56

Finishing the euchromatic sequence of the human genome. Nature (2004) 41.40

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85

Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09

Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17

A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27

Signatures of mutational processes in human cancer. Nature (2013) 21.63

Genome-wide in situ exon capture for selective resequencing. Nat Genet (2007) 19.97

Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94

Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33

Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45

Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08

A landscape of driver mutations in melanoma. Cell (2012) 12.61

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89

Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49

Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42

Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (2014) 5.63

A decade's perspective on DNA sequencing technology. Nature (2011) 5.61

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol (2015) 5.48

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 4.98

An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet (2013) 4.69

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (2013) 4.42

Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science (2015) 4.29

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science (2014) 4.28

Whole exome capture in solution with 3 Gbp of data. Genome Biol (2010) 4.23

Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med (2012) 3.92

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (2015) 3.13

Whole-genome characterization of chemoresistant ovarian cancer. Nature (2015) 3.06

Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol (1987) 3.03

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61

15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet (1977) 2.23

Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med (2014) 2.12

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med (2015) 2.12

Next-generation sequencing platforms. Annu Rev Anal Chem (Palo Alto Calif) (2013) 2.11

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov (2015) 2.07

Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov (2015) 1.76

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov (2015) 1.70

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature (2014) 1.61

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun (2015) 1.50

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res (2014) 1.48

ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Cancer Res (2014) 0.96

Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med (2015) 0.94

Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem (2014) 0.91

Strategies for isolation of exosomes. Cold Spring Harb Protoc (2015) 0.88

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Mol Cancer (2015) 0.87

Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system. J Mol Diagn (2014) 0.82

Liquid biopsies to evaluate early therapeutic response in colorectal cancer. Ann Oncol (2015) 0.81

Comparable complex rearrangements involving 8;21 and 9;22 translocations in leukaemia. Nature (1977) 0.81

Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. Clin Colorectal Cancer (2014) 0.78

The relationship of chromosomal abnormalities to neoplasia. Adv Pathobiol (1976) 0.76